Up to $3 billion in pharmaceuticals currently used in the United States (U.S.) depend on Canadian manufacturing, according to new research findings from the University of Toronto. Applying 25% trade tariffs to these pharmaceuticals could add $750 million in cost to the U.
The Hatch Waxman Act and the Biological Price Competition and Innovation Act have incentivized efforts to improperly prolong the monopolies on existing drugs. It’s time for reform.
3d
KTVU FOX 2 on MSNDrug market sweeps yield a lot of arrests, but few prosecutions in San FranciscoLaw enforcement in San Francisco are standing by large drug market sweeps even if so far, they don't result in a lot of prosecutions.
Drugmakers are pushing back against pharmaceutical tariffs. Some companies are lobbying the Trump administration to phase in or delay tariffs on drugs coming from other countries, according to people
The impact be especially strong on users of some formulations of testosterone, an antidepressant and an anti-brain-bleed drug.
7d
The Punch on MSNPICTORIAL: Anambra drug traders protest market closure by NAFDACTraders at the Ogbo-Ogwu Bridgehead Drug Market in Onitsha, Anambra State, on Tuesday protested the continuous closure of their shops by the National Agency for Food, Drug Administration, and Control.
Bayer said on Tuesday it was preparing market launches this year of two new drugs that could each have annual peak sales of at least $1 billion, as it seeks to strengthen its pharmaceuticals business amid a high debt burden.
The pre-dawn raid, touted by Mayor Daniel Lurie and the San Francisco Police Department, was part of a new “drug market crackdown.”
President Trump threatened to invade Mexico—all in its best interest, of course—in order to smash the drug cartels that are responsible for funneling
Isomorphic Labs, which uses artificial intelligence technologies for drug discovery, has raised $600 million in its first ever external funding round led by Thrive Capital, the startup said on Monday.
The Ukrainian government has instigated rapid cost-cutting measures across the drug retail sector, triggered by reports of overpricing.